Publications by authors named "Hiba Dada"
Clinical trials reporting the robust antitumor activity of immune checkpoint inhibitors (ICIs) in microsatellite instability-high (MSI-H) solid tumors have used tissue-based testing to determine the MSI-H status. This study assessed if MSI-H detected by a plasma-based circulating tumor DNA liquid biopsy test predicts robust response to ICI in patients with pancreatic ductal adenocarcinoma (PDAC). Retrospective analysis of patients with PDAC and MSI-H identified on Guardant360 from October 2018 to April 2021 was performed; clinical outcomes were submitted by treating providers.
View Article and Find Full Text PDFArticle Synopsis
- Adrenocortical carcinoma (ACC) is a rare cancer with poor outcomes, and researchers conducted a study to explore the use of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) to assess genetic changes and identify potential treatments in ACC patients.
- In a retrospective analysis of 120 ACC patients, most had detectable genetic alterations, with common mutations found in genes like TP53 and EGFR, and nearly half of those tested showed actionable mutations that could inform treatment options.
- The study suggests that using blood tests for NGS can effectively reveal genomic insights in ACC, making it feasible for personalized therapies, as the alterations found in blood were similar to those in tissue samples.*
Background: Plasma-based circulating cell-free tumor DNA (ctDNA) genomic profiling by next-generation sequencing (NGS)is an emerging diagnostic tool for pancreatic cancer (PC). The impact of detected genomic alterations and variant allele fraction (VAF) in tumor response to systemic treatments and outcomes is under investigation.
Methods: Patients with advanced PC who had ctDNA profiled at time of initial diagnosis were retrospectively evaluated.
Background: Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced nonsquamous non-small cell lung cancer (aNSCLC). The NILE study was a prospective observational study that demonstrated noninferiority of cell-free circulating tumor DNA (cfDNA)-based tumor genotyping compared to tissue-based genotyping to find targetable genomic alterations in patients with newly diagnosed nonsquamous aNSCLC. As the cohort has matured, clinical outcomes data can now be analyzed.
View Article and Find Full Text PDFPurpose: Recent advances in molecular diagnostic technologies allow for the evaluation of solid tumor malignancies through noninvasive blood sampling, including circulating tumor DNA profiling (ctDNA). Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, often because of late presentation of disease. Diagnosis is often made using endoscopic ultrasound or endoscopic retrograde cholangiopancreatography, which often does not yield enough tissue for next-generation sequencing.
View Article and Find Full Text PDF